{"transactions":[{"id":1347212,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-02T16:30:08.000Z","date":"2024-11-30","kind":"grant","planned":false,"acquired":true,"shares":495,"price":6.154,"value":3046.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on November 29, 2024."}],"balance_after":42995,"source":{"system":"sec-edgar","filing":"0000950170-24-132253","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000095017024132253/ownership.xml","form_type":"4"}},{"id":1482107,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-12T16:30:07.000Z","date":"2024-06-11","kind":"purchase","planned":false,"acquired":true,"shares":12509,"price":4.4257,"value":55361.0813,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.4199 to $4.4299, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":42500,"source":{"system":"sec-edgar","filing":"0000950170-24-072494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000095017024072494/ownership.xml","form_type":"4"}},{"id":1482106,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-12T16:30:07.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":4448,"price":3.7825,"value":16824.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022."}],"balance_after":29991,"source":{"system":"sec-edgar","filing":"0000950170-24-072494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000095017024072494/ownership.xml","form_type":"4"}},{"id":1676432,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T16:30:12.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":145245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":145245,"derivative":{"exercise_price":14.44,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":145245},"source":{"system":"sec-edgar","filing":"0000950170-24-005416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000095017024005416/ownership.xml","form_type":"4"}},{"id":1725528,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-01T17:58:08.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":1345,"price":3.7825,"value":5087.4625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022."}],"balance_after":25543,"source":{"system":"sec-edgar","filing":"0000950170-23-067424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000095017023067424/ownership.xml","form_type":"4"}},{"id":1870004,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-02T17:01:14.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":4273,"price":3.7825,"value":16162.6225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022."}],"balance_after":24198,"source":{"system":"sec-edgar","filing":"0000950170-23-026142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000095017023026142/ownership.xml","form_type":"4"}},{"id":2057528,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-10T17:00:42.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":126300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":126300,"derivative":{"exercise_price":7.05,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":126300},"source":{"system":"sec-edgar","filing":"0000899243-23-001486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000089924323001486/doc4.xml","form_type":"4"}},{"id":2098355,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-02T16:30:38.000Z","date":"2022-11-30","kind":"grant","acquired":true,"shares":2518,"price":3.7825,"value":9524.335,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022."}],"balance_after":19925,"source":{"system":"sec-edgar","filing":"0000899243-22-037438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000089924322037438/doc4.xml","form_type":"4"}},{"id":2118005,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-11-14T16:30:51.000Z","date":"2022-11-11","kind":"purchase","acquired":true,"shares":4100,"price":7.6307,"value":31285.87,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $7.6000 to $7.6499, inclusive. The reporting person undertakes to provide to Biomea Fusion, Inc., any security holder of Biomea Fusion, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 1 to this Form 4."}],"balance_after":17407,"source":{"system":"sec-edgar","filing":"0000899243-22-035697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000089924322035697/doc4.xml","form_type":"4"}},{"id":2249585,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-01T18:00:14.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":3307,"price":4.6665,"value":15432.1155,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the closing price of the Issuer's common stock on May 31, 2022."}],"balance_after":13307,"source":{"system":"sec-edgar","filing":"0000899243-22-020517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000089924322020517/doc4.xml","form_type":"4"}},{"id":2433824,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-18T19:00:23.000Z","date":"2022-01-14","kind":"purchase","acquired":true,"shares":10000,"price":8.6767,"value":86767.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.5550 to $8.7400, inclusive. The reporting person undertakes to provide to Biomea Fusion, Inc., any security holder of Biomea Fusion, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 1 to this Form 4."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-22-002217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000089924322002217/doc4.xml","form_type":"4"}},{"id":2482314,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-07T17:25:27.000Z","date":"2021-12-04","kind":"grant","acquired":true,"shares":144770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":144770,"derivative":{"exercise_price":9.8,"expiration_date":"2031-12-03","underlying":"Common Stock","underlying_shares":144770},"source":{"system":"sec-edgar","filing":"0001567619-21-021720","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000156761921021720/doc1.xml","form_type":"4"}},{"id":2613053,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-05T19:25:33.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer though each vesting date."}],"balance_after":165000,"derivative":{"exercise_price":13.45,"expiration_date":"2031-07-25","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001567619-21-014561","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699848/000156761921014561/doc1.xml","form_type":"4"}},{"id":2892218,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T19:22:38.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":24350,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued From Footnote 1) The option vests over four years after March 28, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued From Footnote 1) The option vests over four years after March 28, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":24350},"source":{"system":"sec-edgar","filing":"0000899243-21-003651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003651/doc4.xml","form_type":"4"}},{"id":2908352,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-13T16:05:07.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":24350,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":1747},"source":{"system":"sec-edgar","filing":"0000899243-21-001847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321001847/doc4.xml","form_type":"4"}},{"id":2908351,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-13T16:05:07.000Z","date":"2021-01-11","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":26097,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0000899243-21-001847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321001847/doc4.xml","form_type":"4"}},{"id":2908350,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2021-01-13T16:05:07.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":1747,"price":125.445,"value":219152.415,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-001847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321001847/doc4.xml","form_type":"4"}},{"id":2908349,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2021-01-13T16:05:07.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":1747,"price":7.24,"value":12648.28,"ownership":{"direct":true},"balance_after":1747,"source":{"system":"sec-edgar","filing":"0000899243-21-001847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321001847/doc4.xml","form_type":"4"}},{"id":2908348,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2021-01-13T16:05:07.000Z","date":"2021-01-11","kind":"sale","acquired":false,"shares":1500,"price":125.605,"value":188407.5,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-001847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321001847/doc4.xml","form_type":"4"}},{"id":2908347,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2021-01-13T16:05:07.000Z","date":"2021-01-11","kind":"exercise","acquired":true,"shares":1500,"price":7.24,"value":10860.0,"ownership":{"direct":true},"balance_after":1500,"source":{"system":"sec-edgar","filing":"0000899243-21-001847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321001847/doc4.xml","form_type":"4"}},{"id":2986682,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-10T16:05:04.000Z","date":"2020-11-09","kind":"exercise","acquired":false,"shares":1623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":27597,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":1623},"source":{"system":"sec-edgar","filing":"0000899243-20-030728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030728/doc4.xml","form_type":"4"}},{"id":2986681,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-11-10T16:05:04.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":1623,"price":74.9287,"value":121609.2801,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $74.82 to $75.12 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-030728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030728/doc4.xml","form_type":"4"}},{"id":2986680,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-11-10T16:05:04.000Z","date":"2020-11-09","kind":"exercise","acquired":true,"shares":1623,"price":7.24,"value":11750.52,"ownership":{"direct":true},"balance_after":1623,"source":{"system":"sec-edgar","filing":"0000899243-20-030728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030728/doc4.xml","form_type":"4"}},{"id":3009440,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-09T17:23:58.000Z","date":"2020-10-08","kind":"exercise","acquired":false,"shares":5199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":29220,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":5199},"source":{"system":"sec-edgar","filing":"0000899243-20-027918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320027918/doc4.xml","form_type":"4"}},{"id":3009439,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-09T17:23:58.000Z","date":"2020-10-07","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":34419,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-20-027918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320027918/doc4.xml","form_type":"4"}},{"id":3009438,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-10-09T17:23:58.000Z","date":"2020-10-08","kind":"sale","acquired":false,"shares":5199,"price":74.8511,"value":389150.8689,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $74.77 to $74.95 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-027918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320027918/doc4.xml","form_type":"4"}},{"id":3009437,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-10-09T17:23:58.000Z","date":"2020-10-08","kind":"exercise","acquired":true,"shares":5199,"price":7.24,"value":37640.76,"ownership":{"direct":true},"balance_after":5199,"source":{"system":"sec-edgar","filing":"0000899243-20-027918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320027918/doc4.xml","form_type":"4"}},{"id":3009436,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-10-09T17:23:58.000Z","date":"2020-10-07","kind":"sale","acquired":false,"shares":5444,"price":75.0823,"value":408748.0412,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $74.9701 to $75.3901 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-027918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320027918/doc4.xml","form_type":"4"}},{"id":3009435,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-10-09T17:23:58.000Z","date":"2020-10-07","kind":"exercise","acquired":true,"shares":5000,"price":7.24,"value":36200.0,"ownership":{"direct":true},"balance_after":5444,"source":{"system":"sec-edgar","filing":"0000899243-20-027918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320027918/doc4.xml","form_type":"4"}},{"id":3120617,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-06-05T16:05:38.000Z","date":"2020-05-31","kind":"grant","acquired":true,"shares":444,"price":41.5735,"value":18458.634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":444,"source":{"system":"sec-edgar","filing":"0000899243-20-015411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320015411/doc4.xml","form_type":"4"}},{"id":3171787,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (right to buy)","published_at":"2020-04-22T16:05:35.000Z","date":"2020-04-20","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":39419,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000899243-20-011154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320011154/doc4.xml","form_type":"4"}},{"id":3171786,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-04-22T16:05:35.000Z","date":"2020-04-20","kind":"sale","acquired":false,"shares":2000,"price":49.79,"value":99580.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $49.69 to $49.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-011154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320011154/doc4.xml","form_type":"4"}},{"id":3171785,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-04-22T16:05:35.000Z","date":"2020-04-20","kind":"exercise","acquired":true,"shares":2000,"price":7.24,"value":14480.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0000899243-20-011154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320011154/doc4.xml","form_type":"4"}},{"id":3192193,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-30T16:23:37.000Z","date":"2020-03-26","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":41419,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-20-009640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320009640/doc4.xml","form_type":"4"}},{"id":3192192,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-03-30T16:23:37.000Z","date":"2020-03-26","kind":"sale","acquired":false,"shares":2000,"price":48.85,"value":97700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $48.71 to $49.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-009640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320009640/doc4.xml","form_type":"4"}},{"id":3192191,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-03-30T16:23:37.000Z","date":"2020-03-26","kind":"sale","acquired":false,"shares":3000,"price":47.87,"value":143610.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $47.37 to $48.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0000899243-20-009640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320009640/doc4.xml","form_type":"4"}},{"id":3192190,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-03-30T16:23:37.000Z","date":"2020-03-26","kind":"exercise","acquired":true,"shares":5000,"price":7.24,"value":36200.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000899243-20-009640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320009640/doc4.xml","form_type":"4"}},{"id":3227862,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-04T16:08:54.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":46419,"derivative":{"exercise_price":7.24,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-006944","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320006944/doc4.xml","form_type":"4"}},{"id":3227861,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-03-04T16:08:54.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":1000,"price":53.06,"value":53060.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-006944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320006944/doc4.xml","form_type":"4"}},{"id":3227860,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-03-04T16:08:54.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":2000,"price":51.96,"value":103920.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $51.92 to $52.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000899243-20-006944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320006944/doc4.xml","form_type":"4"}},{"id":3227859,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":85546,"kind":"person","name":"Valle Franco","position":1,"cik":"0001699848","reported_name":"Valle Franco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President, Finance"}}],"security":"Common Stock","published_at":"2020-03-04T16:08:54.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":3000,"price":7.24,"value":21720.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-006944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320006944/doc4.xml","form_type":"4"}}]}